The Scientist

» pharmaceuticals

Most Recent

With its purchase of Actelion, Johnson & Johnson’s acquires experimental treatments for pulmonary arterial hypertension and several rare diseases.

0 Comments

image: Takeda to Buy Cancer Drug Maker Ariad for $5.2 Billion

Takeda to Buy Cancer Drug Maker Ariad for $5.2 Billion

By | January 10, 2017

The pharma giant’s purchase of the US firm includes the acquisition of investigative cancer drugs.

0 Comments

image: Drug Approval Timeline Same as 20 Years Ago

Drug Approval Timeline Same as 20 Years Ago

By | January 9, 2017

A report finds that new medications still take about 12 years to go from patent to patient.

0 Comments

image: European Drug Regulator Releases Clinical Trial Data

European Drug Regulator Releases Clinical Trial Data

By | October 21, 2016

In the initial steps of a campaign to make clinical reports publicly available, the European Medicines Agency has published data on two recently approved drugs.

0 Comments

image: NYU Halts Studies, Suspends Investigator

NYU Halts Studies, Suspends Investigator

By | June 28, 2016

Experiments conducted at the New York University School of Medicine violated several research standards, according to US Food and Drug Administration investigators.

2 Comments

image: Another Drug Price Hike

Another Drug Price Hike

By | March 28, 2016

Valeant Pharmaceuticals is criticized for jacking up the price of a drug used in assisted suicide.

0 Comments

image: Abbott Acquires Diagnostics Firm

Abbott Acquires Diagnostics Firm

By | February 2, 2016

In a deal worth $5.8 billion, Abbott Laboratories is buying medical test–maker Alere.

0 Comments

image: Shire to Buy Baxalta for $32 Billion

Shire to Buy Baxalta for $32 Billion

By | January 12, 2016

The Dublin-based pharma giant is set to acquire Baxalta, an Illinois-based Baxter spinoff, expanding its rare disease drug portfolio.

0 Comments

image: Thermo Fisher to Acquire Affymetrix

Thermo Fisher to Acquire Affymetrix

By | January 11, 2016

The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.

0 Comments

image: Bayer Enters CRISPR Field

Bayer Enters CRISPR Field

By | December 22, 2015

The pharmaceutical company will spend $335 million on a new venture with biotech startup CRISPR Therapeutics.

0 Comments

Popular Now

  1. Humans Never Stopped Evolving
    Features Humans Never Stopped Evolving

    The emergence of blood abnormalities, an adult ability to digest milk, and changes in our physical appearance point to the continued evolution of the human race.

  2. An Aging-Related Effect on the Circadian Clock
  3. Marching for Science, from Berlin to Sydney
  4. Opinion: Is a Clone Really Born at Age Zero?
Business Birmingham